Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

Trial Profile

Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Uteroglobin (Primary)
  • Indications Asthma; Bronchopulmonary dysplasia; Cough; Respiratory distress syndrome; Respiratory tract infections; Wheezing
  • Focus Therapeutic Use
  • Acronyms rhCC10 Study 2013
  • Sponsors Therabron Therapeutics
  • Most Recent Events

    • 12 Sep 2016 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
    • 12 Sep 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
    • 02 Jun 2016 According to a Therabron Therapeutics media release, the company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to rhCC10, for the prevention of bronchopulmonary dysplasia and chronic respiratory morbidity (CRM) in preterm infants, which supplements the Fast Track Designation recently granted by the FDA for rhCC10 and this trial has been supported, in part, by a grant from the U.S. FDA Office of Orphan Product Development.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top